MeiraGTx Unveils Breakthroughs in Genetic Medicine at ESGCT 2025
MeiraGTx, a leading player in genetic medicine, is set to showcase its latest advancements at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress in Seville, Spain. The company will present two posters detailing its innovative work in viral vector optimization and manufacturing processes.
MeiraGTx's poster P0089 introduces novel adeno-associated virus (AAV) capsids designed for intravitreal delivery. These capsids were developed through directed evolution in non-human primate eyes and validated in human retinal organoids, demonstrating the company's commitment to real-world applicability.
Poster P0170 delves into the company's manufacturing prowess, showcasing the scale-up of a perfusion-based AAV manufacturing process to 40L bioreactors. This achievement is a testament to MeiraGTx's proprietary manufacturing platform, which boasts leading yield and quality aspects, and is ready for commercial use.
The company's focus on common diseases, increasing efficacy, addressing novel targets, and expanding access is evident in its four late-stage clinical programs. These programs use local delivery of small doses for disease modification across various indications.
MeiraGTx's presentations at ESGCT 2025 highlight the company's dedication to innovation and excellence in genetic medicine. With its proprietary manufacturing platform, optimized viral vectors, and end-to-end in-house manufacturing capabilities, MeiraGTx is well-positioned to advance its mission of applying genetic medicine to common diseases. The posters are available on the company's website for those unable to attend the congress.
Read also:
- HLC Approves ₹4,645.60 Crore for Flood Recovery and Wetland Rejuvenation in Nine States
- Crooked House Pub's Demolition: Council Orders Rebuild, Debate on Historic Building Protections
- Shaping India's Economic Progression: Readying the Financial System for Tomorrow
- Ethiopia's Grand Dam: 15,000 Lives Lost, Water Concerns Unresolved
